IP Library Granted Patent US 7,678,764
Granted Patent B2
US 7,678,764 · App. 12/145,016 · Granted Mar 16, 2010

Protein formulations for use at elevated temperatures

Assignee: Johnson & Johnson Regenerative Therapeutics, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,678,764
App. No.
12/145,016
Granted
Mar 16, 2010
Kind
B2
Abstract

Liquid formulations of bone morphogenetic proteins are provided for prolonged use at elevated temperatures. More specifically, the invention relates to liquid formulations comprising rhGDF-5, trehalose, and one or more biocompatible excipients that provide stability to the protein for at least 30 days at temperatures up to body temperature.

Claims (12)

1. A composition comprising GDF-5 and excipients in an acidic solution, wherein the excipients are trehalose, present in the amount of 60% w/v, an amino acid, and a trialkylammonium salt.

2. The composition of claim 1 wherein the amino acid is selected from the group consisting of β-alanine, L-glycine, and L-proline.

3. The composition of claim 2 wherein the amino acid is comprised of β-alanine present in an amount of from about 0.25% to about 5% w/v.

4. The composition of claim 3 wherein the β-alanine is present in an amount of about 0.5% w/v.

5. The composition of claim 1 wherein the trialkylammonium salt is present in an amount of from about 0.1% to about 3% w/v.

6. The composition of claim 5 wherein the trialkylammonium salt is triethylammonium hydrochloride.

7. The composition of claim 1 wherein the amino acid is present in an amount of from about 0.25% to about 5% w/v and the trialkylammonium salt is present in an amount of from about 0.1% to about 3% w/v.

8. The composition of claim 7 wherein the amino acid is β-alanine present in an amount of about 0.5% w/v and the trialkylammonium salt is triethylammonium hydrochloride present in an amount of about 0.1% w/v.

9. The composition of claim 1 further comprising the heat shock protein HSP 70 present in an amount of from about 0.1% to 0.2% w/v.

10. The composition of claim 1 further comprising β-alanine present in an amount of about 0.5% w/v and taurine present in an amount of about 0.1% w/v.

11. The composition of claim 1 further comprising a betaine present in an amount of about 0.5% w/v.

12. A method for stabilizing a GDF-5 solution comprising providing GDF-5 in an acidic solution, adding an amount of trehalose to provide 60% w/v solution of trehalose, and adding an amino acid, and a trialkylammonium salt.

Assignments (2)
CHANGE OF NAME Recorded Feb 22, 2011
From: JOHNSON & JOHNSON REGENERATIVE THERAPEUTICS, LLC
To: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
Reel/Frame 025842/0135 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2009
From: GARIGAPATI, VENKATA; SU, DONGLING; LOPEZ, JULIUS
To: JOHNSON & JOHNSON REGENERATIVE THERAPEUTICS, LLC
Reel/Frame 023681/0059 →
Continuity (2)
Provisional Application 6094709200 · Jun 29, 2007
Related Publication 20090318343A1 · Dec 24, 2009